Abstract:Abstract Background Crohn’s disease (CD) is an inflammatory bowel disease with chronic course and exacerbations. Diagnosis and follow-up are based on clinical activity, biomarkers, ileocolonoscopy and imaging techniques. Intestinal ultrasound (IUS) has been shown to have high sensitivity and specificity analyzing inflammatory activity in CD. The aim of our study is to correlate IUS parameters with clinical activity and biomarkers in CD. Methods Retrospective, observational, single-center study was designed. Adult patients with CD who underwent IUS between September 2020 and May 2021 were included. Exclusion criteria was exclusive colonic involvement. Examination was done by ultrasound machine (Hitachi Ascendus) with low frequency curved-array (1–5 MHz) and high-frequency linear-array (5–13 MHz) transducers. Examination assessed bowel wall thickness, mesenteric fat hypertrophy, lymph nodes, hyperemia on color Doppler flow measured as Limberg index and length of affected segment (cm). Clinical activity score for CD was assessed by Harvey Bradshaw index (HBI). Biomarkers parameters studied were C-reactive protein (CRP) and faecal calprotectin (FC). Results are shown as percentages, median and interquartile range (IQR). Data were analysed using Spearman′s correlation analysis Results 121 patients were included (median age 45.6 years (IQR 33.4 – 59.6), 56.2% female). 78.5% had ileal disease and 21.5% ileocolonic involvement. At the time of IUS 17.4% of patients were not taking any maintenance treatment, 13.2% were on azathioprine, 48.8% on anti-TNF (61% adalimumab; 39% infliximab) and 8.3% on ustekinumab. 85.1% patients had HBI <6, 14.1% had moderate activity. Median CRP level was 0.334 mg/dl (IQR 0.06–1.12), FC was 141 μg/g (IQR 35–386). Median wall thickening was 4.7 mm (range 4.1–5.6), 68.6% of patients had mesenteric fat hypertrophy and 73.55% had lymph nodes. Limberg index was 0 in 20.7%, 1 in 23.1%, 2 in 37.2% and 3 in 19% of patients. IUS determined treatment modification in 60.3% of cases: 19% started biological therapy, 15.7% changed biological target, 14.9% underwent intensification or reinduction of biological treatment, in 1.7%, treatment reduction was decided. The Spearman′s correlation between IUS parameters, clinical and biochemical markers is presented in Table 1. IUS parameters were significantly associated with faecal calprotectin and CRP level, specially Limberg Index and faecal calprotectin (r=0.56, p<0.05) and Limberg Index and CRP level (r= 0.38, p<0.05) (Figure 1 and 2). No correlation was observed between HBI and IUS parameters. Conclusion Through this study, significant correlation between IUS and biomarkers was observed in CD. IUS has been shown to be useful for monitoring CD activity in order to optimize patients′ treatment.

Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices

RELATIONSHIP OF THE BIOMARKERS FECAL CALPROTECTIN, C-REACTIVE PROTEIN, AND TMAO WITH CROHN'S DISEASE ACTIVITY

P243 Relationship between intestinal ultrasound, fecal calprotectin and Harvey-Bradshaw Index in the assessment of infllamatory activity in Cronh′s Disease

P138 Novel serum markers for predicting disease activity in ulcerative colitis: results from a retrospective case-control study

Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease

Efficacy of Noninvasive Evaluations in Monitoring Inflammatory Bowel Disease Activity: A Prospective Study in China

Assessing the correlation between fecal calprotectin, blood markers and disease activity in pediatric inflammatory bowel disease

The predictive ability of inflammatory biomarkers in patients with newly diagnosed Inflammatory Bowel Disease [IBD]: Analyses of preliminary pre‐ and post‐therapy data

The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients

Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease

P317 Diagnostic accuracy of plasma calprotectin and serum calprotectin in patients with suspected Crohn’s disease

Comparison of Fecal Calprotectin with Different Endoscopic Scores in the Assessment of Ulcerative Colitis (UC) Activity and Its Utility in Differentiating IBS from IBD

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD

The synergy of dual faecal immunochemical and faecal calprotectin testing for accurate assessment of endoscopic and histological activity in inflammatory bowel disease

Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

Intestinal barrier biomarkers in clinical evaluation of patients with inflammatory bowel disease

P369 Altered fecal bile acid composition in active Ulcerative Colitis